Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,538 signal articles · 191 in last 24h · 133,463 total before filter · latest 1h ago
191last 24h
1079last 7d
177● bullish (7d)
123● bearish (7d)
208publishers
AllMacro267Earnings373M&A72Regulatory27Product10Analyst16
✕ clear all filterssentiment: bullishSentiment:bullishneutralbearishshow all (incl. clickbait)
Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers
Bloomberg15d agobullishVIDEO
Moderna Surges on Cancer Vaccine; Estee Lauder Rallies on Earnings | Stock Movers

On this episode of Stock Movers: - Shares of Moderna (MRNA) surged by a record 101% - the stock's biggest intraday gain on record - after the biotech said a personalized cancer vaccine combined with partner Merck & Co.'s Keytruda helped cut the recurrence of melanoma in a large, late-stage trial. The study also met a key secondary goal of showing the shot could help prevent tumors from spreading to new areas of the body, the companies said in a statement Wednesday. - Shares of Estee Lauder (EL) rallied after the beauty company's adjusted earnings per share and sales metrics topped consensus expectations for the fourth quarter. The midpoint of fiscal 2027 organic sales and adjusted EPS guidance ranges are above Street views. - Shares of La-Z-Boy (LZB) tumbled at the open after the furniture maker's forecast sales for the second quarter missed the average analyst estimate.

Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test
Associated Press15d agobullish
Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test

Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based on unique mutations within their tumors. In current studies, they are pairing it with Keytruda, a immunotherapy drug made by Merck.

Eshallgo Secures Exclusive North American Distribution Partnership With Zhongshan Senwei
InvestorsHub15d agobullish
Eshallgo Secures Exclusive North American Distribution Partnership With Zhongshan Senwei

Eshallgo’s California subsidiary will exclusively distribute Zhongshan Senwei printing consumables in North America, initially targeting major e-commerce channels as the company builds its overseas operations. Key Investor TakeawaysEshallgo (NASDAQ:EHGO) has secured an exclusive North American distribution partnership with Chinese printing consumables manufacturer Zhongshan Senwei.

Estée Lauder shares surge on earnings beat, raised margin guidance
Proactive15d agobullish
Estée Lauder shares surge on earnings beat, raised margin guidance

Estee Lauder Companies Inc (NYSE:EL, XETRA:ELAA) shares jumped more than 15% on Wednesday after the beauty group posted fourth-quarter results that beat Wall Street estimates and raised its profit margin outlook for fiscal 2027. The company reported revenue of $3.6 billion for its fiscal...

TJX Q2 earnings beat expectations with strong margins
Proactive15d agobullish
TJX Q2 earnings beat expectations with strong margins

TJX Companies Inc (NYSE:TJX) reported second-quarter profit and revenue above Wall Street estimates on Wednesday, as the off-price retailer's discount model continued to draw shoppers, though shares fell 1.3% at the open. The parent of TJ Maxx, Marshalls and HomeGoods posted adjusted earnings...

Target boosts 2026 outlook after Q2 sales and earnings beat
Proactive15d agobullish
Target boosts 2026 outlook after Q2 sales and earnings beat

Target Corp (NYSE:TGT) has raised its full-year outlook after reporting stronger-than-expected second quarter results. For the quarter, sales were up 5.3% year-over-year at $26.54 billion, ahead of Wall Street estimates of $26.13 billion. Comparable sales increased 3.8% year over year, while...

Estée Lauder Stock Surges as Earnings Show Growth Plan Is Working
Barrons.com15d agobullish
Estée Lauder Stock Surges as Earnings Show Growth Plan Is Working

Shares of Estée Lauder advanced on Wednesday as the beauty and cosmetics giant’s better-than-expected quarterly earnings showed Wall Street its growth plan is well underway. The company announced adjusted earnings of 39 cents a share in the fiscal fourth quarter, up from 9 cents a year ago and above Wall Street’s expectation of 32 cents. Estée Lauder reported adjusted earnings of $2.51 a share for the full fiscal year, up from $1.51 last year.

Marti Technologies Shares Rise After Revenue Beat and Higher Guidance
InvestorsHub15d agobullish
Marti Technologies Shares Rise After Revenue Beat and Higher Guidance

Marti Technologies, Inc. (AMEX:MRT) shares gained 5% in pre-market trading on Wednesday after the Turkish mobility super app delivered second-quarter revenue well above expectations and raised its full-year outlook, despite reporting a wider-than-expected adjusted loss per share.

Marvell gives Google option to buy $12.2 billion stake in custom chip deal
Reuters15d agobullish
Marvell gives Google option to buy $12.2 billion stake in custom chip deal

Marvell Technology said on Wednesday it has issued ‌Alphabet's Google a warrant to ‌buy a stake worth about $12.18 billion as ​part of a deal to help develop custom chips for the search giant. Shares of the custom chipmaker jumped ‌more than ⁠11% in premarket trading, while larger rival Broadcom was ⁠down over 3%. Demand for custom chips such as Google's tensor processing units (TPUs), ​used for ​AI workloads, ​has surged in ‌recent years as businesses seek alternatives to Nvidia's pricey graphics processors.

Analog Devices' quarterly forecast tops estimates on AI-fueled chip demand
Reuters15d agobullish
Analog Devices' quarterly forecast tops estimates on AI-fueled chip demand

Analog Devices forecast fourth-quarter revenue and profit above Wall Street estimates on ‌Wednesday, betting on continued demand for its power-management ‌chips used across data centers and industrial applications as AI ​investments ramp up. The company stands to benefit from surging investment in AI-driven computing, which has boosted demand for chips that regulate power and move vast amounts of ‌data. Its components ⁠are widely used in data centers, factory automation equipment and modern vehicles.

Alibaba or NetEase: Which Stock Could Soar After Earnings?
24/7 Wall St.15d agobullish
Alibaba or NetEase: Which Stock Could Soar After Earnings?

Alibaba and NetEase both report earnings the same morning, forcing a direct choice between two very different China tech bets. Analyst sentiment, price targets, and crowd prediction markets all point in conflicting directions, and only one stock survives the growth test.

Lowe's (LOW) Q2 Earnings Beat Estimates
Zacks15d agobullish
Lowe's (LOW) Q2 Earnings Beat Estimates

Lowe's (LOW) delivered earnings and revenue surprises of +4.27% and -0.68%, respectively, for the quarter ended July 2026. Do the numbers hold clues to what lies ahead for the stock?